Biotech Drug Report Generated Jul 7, 2026

GX-03

TTRX·Turn Therapeutics Inc.

BULLISH

Drug Impact Rating8/10

Trial Phase: Phase 2
Time to Market: ~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
Why 8/10: The next hard catalyst is the Phase 2 Stage 2 topline data readout, expected in Q4 2026 (~3-5 months away), plus a planned Type-B FDA meeting also in Q4 2026. GX-03 is Turn Therapeutics' lead asset, and the company's valuation is overwhelmingly tied to this program. Score 8 = dated binary within ~6 months on the lead asset driving most of the thesis.

Actionable Insight BULLISH

GX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).

Price Chart

Loading chart...

Executive Summary

GX-03 is Turn Therapeutics' lead investigational drug — a first-in-class topical cream targeting IL-36 and IL-31 cytokines for moderate-to-severe atopic dermatitis (eczema). The company is currently running an adaptive Phase 2 trial. Interim data on the first 50 subjects (June 2026) showed strong efficacy: 92.6% of patients achieved at least a 50% reduction in eczema severity (EASI-50) at week 4, with 70.4% achieving EASI-75 and 44.4% EASI-90. No treatment-related serious adverse events were reported. The trial has been expanded to ~120-135 patients across the full severity spectrum, with topline results expected in Q4 2026 alongside a planned FDA Type-B meeting. Turn Therapeutics went public via direct listing in late 2025, has $11.2M cash plus a $25M loan facility, and analyst consensus is strongly bullish (6 buy/strong-buy, 1 hold).

How It Works

GX-03 is a topical cream (applied directly to the skin) that acts as a first-in-class topical inhibitor of IL-36 and IL-31 — two inflammatory signaling molecules (cytokines) that drive the redness, itching, and skin damage in eczema/atopic dermatitis. Unlike existing treatments that are injected (biologics) or broadly suppress the immune system (steroids, JAK inhibitors), GX-03 works locally at the skin surface using an extended-release formulation of polyhexanide, designed to deliver biologic-level efficacy without systemic side effects.

Trial Status

Phase 2 adaptive trial with two stages. Stage 1 (first 50 subjects) completed with positive interim results announced June 1, 2026. Stage 2 expansion announced July 7, 2026, enrolling ~120-135 patients across the full atopic dermatitis severity spectrum (EASI ≥1.1). Topline data expected Q4 2026. A Type-B meeting with FDA also anticipated in Q4 2026. No serious adverse events reported to date.

The Two-Sided Case

▲ Bull Case6

Interim Phase 2 data (N=50) showed compelling efficacy — 92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at Week 4, with 79.43% mean EASI reduction vs 50.55% vehicle (source: SEC 8-K filed June 3, 2026, via businesswire.com).

Zero treatment-related serious adverse events and no discontinuations; safety profile appears clean (source: SEC 8-K filed July 7, 2026, via sec.gov).

First-in-class topical IL-36/IL-31 inhibitor — novel mechanism that avoids systemic immunosuppression of JAK inhibitors or steroids; could differentiate in a crowded AD market (source: turntherapeutics.com).

Trial expanded to full AD severity spectrum (EASI ≥1.1) with FDA-recognized Hochberg multiple-testing procedure, indicating FDA engagement and regulatory pathway clarity (source: SEC 8-K filed July 7, 2026).

Analyst consensus strongly bullish: 6 buy/strong-buy vs 1 hold; mean price target $8 vs ~$3.70 current price (~116% implied upside as of May 2026).

Borrowing capacity via $25M Avenue Capital facility plus $11.2M cash provides runway through at least Q1 2027 (source: SEC 10-Q filed May 11, 2026, via last10k.com).

▼ Bear Case6

Phase 2 Stage 1 data came from small subgroups (n=13-14 GX-03, n=12-18 vehicle) — numbers may not replicate in the larger Stage 2 population of ~120-135 patients (source: SEC 8-K analysis report, July 7, 2026).

High vehicle/placebo response (50.55% EASI reduction) could dilute the treatment effect in later-stage, larger trials.

Crowded atopic dermatitis market includes approved topicals (Opzelura/ruxolitinib, Eucrisa/crisaborole, Protopic/tacrolimus, Zoryve/roflumilast) and injectable biologics (Dupixent, Adbry). No head-to-head data vs these standards.

Cash runway is limited — $11.2M with operations burning cash; only enough into Q1 2027 (or Q3 2027 with debt facility). Phase 3 would require additional capital, likely via dilutive financing (source: SEC 10-Q).

No generic/INN name assigned yet; still in early-to-mid clinical development with a long path to approval (Phase 3 not yet started).

Stock is thinly traded with low volume, suggesting limited institutional interest; Millennium Management trimmed its position in Q1 2026.

Upcoming Catalysts

Q4 2026: Phase 2 Stage 2 topline data readout (~120-135 patients, full AD spectrum).
Q4 2026: Planned Type-B meeting with FDA to discuss regulatory pathway and potential accelerated development.
Enrollment completion milestones for Stage 2 (ongoing).
Potential data presentations at dermatology conferences (e.g., AAD annual meeting).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Turn Therapeutics Inc. 8-K TTRX ·Originating report

Sources · 13

Hover a chip for the title

1 businesswire.com2 biospace.com3 turntherapeutics.com4 turntherapeutics.com5 turntherapeutics.com6 businesswire.com7 last10k.com8 stockanalysis.com9 sec.gov10 sec.gov11 dermatologytimes.com12 turntherapeutics.com13 dermatologytimes.com